Entospletinib
- Generic Name
- Entospletinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21N7O
- CAS Number
- 1229208-44-9
- Unique Ingredient Identifier
- 6I3O3W6O3B
- Background
Entospletinib has been used in trials studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and Non-Hodgkin Lymphoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 66
- Registration Number
- NCT01796470
- Locations
- 🇺🇸
University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath